Opiant Pharmaceuticals 

Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 3 full-time employees. The firm develops pharmacological treatments for substance use, addictive and eating disorders. The firm has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The firm's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The firm also is focused on other treatment opportunities.